权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bringing 4π radiation therapy to the clinic

将 4° 放射治疗引入诊所

基本信息

批准号：
10618889
负责人：
Ke Sheng
金额：
$ 119.97万
依托单位：
CELESTIAL ONCOLOGY INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-06 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10618889
关键词：
Acceleration Adoption Algorithms Automation Award Businesses Cancer Patient Certification Clinic Clinical Clinical Research Computer software Development Disease Dose Extravasation Fluoroscopy Freedom Funding Grant Head Image Investments Life Linear Accelerator Radiotherapy Systems Lung Neoplasms Malignant neoplasm of lung Maps Marketing Mathematics Mechanics Motion Names Oncology Organ Patients Phase Preparation Publications Radiation Dose Unit Radiation Tolerance Radiation therapy Radiometry Risk Robot Robotics Roentgen Rays Series Site Small Business Innovation Research Grant Solid Source System Systems Integration Testing Three-Dimensional Image Three-Dimensional Imaging Time Translating Treatment-related toxicity United States National Institutes of Health Validation arm cancer therapy clinic ready clinical application cohort commercialization design detector dosimetry flexibility image guided image guided radiation therapy imaging modality improved innovation manufacture novel optimal treatments reconstruction research and development response robotic system success tumor

项目摘要

Significance/Innovation: Utilizing non-coplanar beams in radiotherapy can significantly improve dosimetry for better normal organ sparing and tumor targeting. However, the optimality of such therapy requires extensive and efficient utilization of non-coplanar beams that are incompatible with existing radiotherapy platforms. The widely available C-arm gantry systems are collision prone, cumbersome, and require undesirable patient couch motion to achieve the non-coplanar angles. The existing robotic system lacks posterior beams and a planning system to integrally optimize beam orientation and fluence, making it extremely limited in achievable dosimetry, target sizes, applicable disease sites, and throughput. Motivated by these clinical and market needs UCLA and RadiaBeam are developing a new robotic radiotherapy platform called Polaris that overcomes the limitations of existing radiotherapy systems, with the following innovative advantages: 1. A super compact 6MV linear accelerator enables unobstructed access to 4π solid angle, including posterior beams. 2. A mathematical framework for integrated beam orientation, source-to-tumor distance, and fluence map optimization, which can efficiently create substantially better plans than the clinical state-of-the-art. 3. A 3D image guidance system will be implemented for the first time on a robotic radiotherapy system without impeding the degrees of freedom in non-coplanar delivery. 4. The combination of hardware and software allows superior dosimetry to be efficiently delivered to targets of all sizes, making our system a superior replacement of all C-arm gantry systems and the existing robotic radiotherapy system as a general-purpose radiotherapy machine. During the SBIR project (NIH Phase II 5R44CA183390-04), Celestial Oncology Inc. was founded to bring the Polaris system to market, and received a $6M series A investment in 2020. This NIH SBIR Phase IIB bridge project will accelerate the completion of the last technical, regulatory, and clinical steps required to bring this life-saving therapy to the clinic. We propose the following aims: Aims: 1a: Mechanically synchronize the X-ray source and detector robots. 1b. Collect projections for circular and helical trajectories for CBCT reconstruction. 1c. Integrate the imaging component for end-to-end IGRT accuracy validation. 2a. Complete the design, manufacturing, verification, and validation of the clinical system. 2b. Submit for US market clearance. 2c. Establish and certify a Quality Management System. 3a. Installation and acceptance tests of the 4π radiotherapy system at UCLA. 3b. Early phase clinical study. Impact: Polaris will serve as a superior replacement of all general-purpose machines with advantages in dose conformity, automation, and throughput. These advantages will drive rapid adoption. The success of this project will clear the last hurdles between the current level of technical development and what is needed to be commercially and clinically ready.

意义/创新：在放射治疗中使用非共面射束可以显著提高更好地保留正常器官和肿瘤靶向。然而，这种治疗的最佳效果需要广泛的以及有效利用与现有放射治疗平台不兼容的非共面射束。这个广泛使用的C形臂龙门系统容易碰撞、笨重，并且需要不受欢迎的患者沙发运动实现了非共面角度。现有的机器人系统缺乏后梁和规划系统，以整体优化束流方向和注量，使其在可实现的剂量学中受到极大限制，目标大小、适用的疾病部位和吞吐量。在这些临床和市场需求的推动下，加州大学洛杉矶分校和RadiaBeam正在开发一种新的机器人名为Polaris的放射治疗平台，克服了现有放射治疗系统的限制，具有以下创新优势：1.超紧凑的6 MV直线加速器可让您畅通无阻地 4π立体角，包括后梁。2.用于综合波束定向的数学框架，源到肿瘤的距离和通量图优化，可以有效地创建更好的计划而不是临床上最先进的技术。3.3D图像制导系统将首次在不阻碍非共面投放自由度的机器人放射治疗系统。4. 硬件和软件的组合允许将卓越的剂量测量有效地提供给所有目标尺寸，使我们的系统成为所有C形臂龙门系统和现有机器人的卓越替代品放射治疗系统作为一种通用的放射治疗机。在SBIR项目(NIH第二阶段5R44CA183390-04)期间，天文肿瘤公司成立，以带来北极星系统推向市场，并在2020年获得了600万美元的首轮投资。这座NIH SBIR IIB期大桥项目将加快完成实现以下目标所需的最后技术、法规和临床步骤把救命治疗带到诊所。我们提出以下目标：目标：1A：对X射线源和探测器机器人进行机械同步。1B.收集圆形的投影以及用于CBCT重建的螺旋轨迹。1C。集成用于端到端IGRT的成像组件准确性验证。2A。完成临床系统的设计、制造、验证和确认。 2B。提交美国市场清关申请。2C。建立并认证质量管理体系。3A.安装以及加州大学洛杉矶分校的4π放射治疗系统的验收测试。3B.早期临床研究。影响：北极星将成为所有通用机器的卓越替代品，在剂量上具有优势合规性、自动化和吞吐量。这些优势将推动快速采用。这件事的成功项目将清除当前技术开发水平与需要达到的水平之间的最后障碍在商业和临床上都做好了准备。